Key result
Older adults taking ARBs exhibited higher CSF Aβ, lower P-tau, and a reduced rate of progression to dementia compared to those taking other or no antihypertensives.
Why the study?
Do angiotensin II AT1-receptor blockers reduce cerebral amyloid retention and progression to dementia in stroke-free and dementia-free older adults?
Population
871 stroke-free and dementia-free older adults from the Alzheimer's Disease Neuroimaging Initiative study
Comparison
Angiotensin II AT1-receptor blockers (ARBs) vs Other antihypertensives or no antihypertensives
Design
Cohort
Follow-up
12 and 24 months for lumbar puncture subgroup; variable…
Authors
Loading...
ARB use should not yet change prescribing; leaves open neuroprotective effects on amyloid and dementia in RCTs.
Cohort (n=871)
Do angiotensin II AT1-receptor blockers reduce cerebral amyloid retention and progression to dementia in stroke-free and dementia-free older adults?
ARB use in older adults is associated with attenuated age-related decreases in CSF Aβ and reduced progression to dementia, suggesting a potential neuroprotective effect.
Nation et al. (2016) conducted a cohort in Dementia (n=871). Angiotensin II AT1-receptor blockers (ARBs) vs. Other antihypertensives or no antihypertensives was evaluated on Cerebrospinal fluid (CSF) Aβ and phosphorylated tau (P-tau) levels, and progression to dementia. Older adults taking ARBs exhibited higher CSF Aβ, lower P-tau, and a reduced rate of progression to dementia compared to those taking other or no antihypertensives.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: